A human immunodeficiency virus-negative male was successfully treated for two occurrences of Burkitt's lymphoma. 15 years apart. As consolidation of his second remission, he underwent high-dose chemotherapy with peripheral blood stem cell transplantation. In an effort to prove whether the second lymphoma was a relapse of the first or a second primary lymphoma, we obtained paraffin-embedded material from both lymphomas. DNA was extracted from this material and amplified by polymerase chain reaction (PCR) using consensus JH and VH region primers. Analysis of the PCR products, which mostly reflects VDJ joints, showed two sharp bands of different molecular size, proving the mono-URKITT'S LYMPHOMA (BL) is an aggressive, rapidly proliferating malignancy of B-cell rigi in."^ All BLs have translocations involving 8q within or near the cmyc gene.' The partner in these translocations is either the Ig heavy-chain gene [t(8; 14)] or the K -[t(2;8)] or A- [t(8;22)] light chain genes. The c-myc gene may be structurally altered and abnormally regulated as a consequence of these translocations. Its transcription is associated with the malignant phenotype.
B CASE REPORT
The patient is a 28-yea.r-old, HIV-negative, man who presented to the hospital with abdominal pain, a palpable abdominal mass, and small bowel obstruction in December 1978 at the age of 11 years. Laparotomy was performed that showed extensive intra-abdominal disease, with a tumor mass measuring 15 cm in diameter, encasing the small bowel. The biopsy specimen showed a BL. Intravenous chemotherapy was administered at monthly intervals for 1 year. Prophylactic intrathecal methotrexate was also administered. He rapidly achieved complete remission with resolution of all symptoms. The patient remained in complete remission without any treatment until December 1993. Then, at 27 years of age, he presented to the hospital with an extensive abdominopelvic mass, abdominal pain, and bowel obstruction. At laparotomy, extensive abdominal tumor was found, and a biopsy specimen was again consistent with BL. The bone marrow and cerebral spinal fluid (CSF) were not involved, but his lactic dehydrogenase level was elevated to 3 times the upper limit of normal. He was treated with 7 cycles of monthly chemother- apy (cyclophosphamide, doxorubicin, vincristine, prednisone-methotrexate [CHOP-M]) and 6 intrathecal chemotherapy treatments with methotrexate and cytarabine. At the end of this therapy, he had achieved a complete remission. He was subsequently referred to the University of Pittsburgh Cancer Institute (Pittsburgh, PA) for highdose chemotherapy and peripheral blood stem cell transplantation (unique patient number 545) as consolidation therapy for his second remission. He gave informed consent for treatment and received the transplant in August 1994. He engrafted quickly, with an absolute neutrophil count (ANC) of 500/pL on day + 13 and a platelet count of 50,00O/pL on day +14. The patient has completed all therapy and is now in continuous complete remission, 526 days after transplantation. There was no family history of lymphoproliferative disease.
MATERIALS AND METHODS

Histopathology
Histological sections from two blocks of the ileal mass (hematoxylin and eosin [H&E] , periodic acid-Schiff [PAS], methyl green pyronin [MGP] ) and one block of a regional lymph node (H&E), resected in 1978, and two blocks of the retroperitoneal mass (H&E, PAS, MGP), both from 1993, were prepared and reviewed. In addition, sections from the ileal and retroperitoneal mass were immunostained with CD20 (L26; Dako Corp, Carpenteria, CA) and polyclonal CD3 (Dako Corp) antibodies using an avidin-biotin complex immunoperoxidase procedure (Vector Elite ABC reagent; Vector, Burlingame, CA).
Molecular Genetic Characterization
Polymerase chain reaction (PCR) analysis. Tissue was scraped off glass slides that contained a 6-pm-thick paraffin-embedded section and was incubated in 100 pL of digestion buffer ( I O mmolL Tris-HCL, 50 mmol/L KCI, 1.5 mmol/L MgCIZ, 400 pglmL Proteinase K, 1% sodium dodecyl sulfate) overnight at 55°C. After IO minutes of incubation at 95°C and centrifugation at 4"C, 4 pL of digest was amplified for 37 cycles using 5' consensus Ig heavychain variable (V,) and 3' joining ( J H ) region primers in a total volume of 50 pL, using standard conditions as described." The primers, which are shown in Fig 3, are designed to specifically amplify most Ig heavy-chain VDJ joints or CDR3 regions that serve as clonal markers because of their marked variability.'6 After amplification, approximately one third of the resultant PCR products was electrophoresed in 8% polyacrylamide gels and was visualized by staining with ethidium bromide.
DNA sequencing. PCR products were purified using Wizard PCR Preps (Promega, Madison, WI) and cloned using the pCRScript Cloning Kit (Stratagene, La Jolla, CA) following the manufacturer's directions. Plasmid DNA was isolated from overnight cultures of randomly selected white colonies (those that contained plasmids with inserts) using Wizard Minipreps (Promega). Dideoxynucleotide sequencing was performed with Sequenase (US Biochemical, Cleveland, OH) following the manufacturer's protocol for a doublestranded plasmid, using approximately one third of the isolated DNA and the MI3 reverse primer.
RESULTS
Histopathology
The histological sections from 1978 showed an ulcerated portion of bowel with a transmural lymphoid infiltrate most consistent with a Burkitt-like small noncleaved follicular center cell lymphoma (Fig 1) . Numerous mitotic figures, apoptotic cells, and tingible body macrophages created a starry-sky appearance. Paraffin-section immunoperoxidase stains confirmed the B-cell origin of the neoplastic cells (CD20', CD3-). A regional lymph node showed focal intrafollicular and interfollicular involvement.
Histological sections from the biopsy of the retroperitoneal mass obtained in 1993 were very similar to those of the ileal mass from 1978 (Fig l) , except for the presence of large areas of necrosis and more numerous apoptotic cells lying singly and in clusters, aggregates, and sheets. Paraffinsection immunoperoxidase stains again confirmed the B-cell origin of the neoplastic cells (CD20'. CD3-). A staging bone marrow aspirate and biopsy specimen did not show lymphoma. For Fig 2) were cloned, and three randomly selected clones were sequenced from both specimens. The consensus sequences for the 1978 (top) and 1993 (bottom) lymphomas are shown. The V-and J-segment contributions are separated from the nDn regions, which represent the diversity segment and possible N nucleotides on either side. The sequences recognized by the primers used for amplification are indicated by lines above the top sequence.
Molecular Genetic Clmracterization
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Fig 3. Lymphoma VDJ sequences. The lymphoma PCR products (see
electrophoresed under conditions that permitted resolution of small differences in size. As shown in Fig 2, an intense, single band, indicative of a dominant monoclonal population was observed for both the 1978 and 1993 specimens. As expected, the polyclonal control specimen produced a broad ladder of faint bands reflecting the different size VDJ joints. The different sizes of these bands suggested that the two lymphomas were different clones. To confirm these results, the PCR products from both lymphomas were cloned, and three randomly selected clones from each were sequenced. With the exception of one point mutation in a single clone, the three clones analyzed from each specimen had identical VDJ joint sequences, indicating that they represent clonal B-cell expansions. Moreover, as shown in Fig 3, the VDJ joint sequences of the two lymphomas are different, but both are potentially functional genes because they are in-frame and do not generate stop codons. Because there are over 30 diversity gene segments (D), unrelated clones would probably use different D segments, which appears to be the case here. None of the known D segments has significant homology with the 1978 D region. However, the 1993 D region matches in eight of nine positions with the Dlr2 segment. Both lymphoma heavy chains appear to be using 54, which is the most commonly used of the six potentially functional J H segments, being found in more than 50% of heavy-chain rearrangements." Thus, usage of the same 54 segment does not provide evidence for identity between two clones.
DISCUSSION
Most relapses of BL occur within the first year from complete remission."'3J4J8 Identity of Ig gene rearrangements between initial and recurrent disease would prove that both originated from the initial lymphoma. Sufficient dissimilarity would strongly suggest two separate clonal origins of initial and recurrent disease. Although somatic mutation may result in alterations in the VDJ region, in our case, the sequence differences identified are sufficiently great to suggest that this is only a remote possibility. Moreover, there is little evidence for somatic mutation of VH genes occurring in vivo within any BL." Although Chapman et al'" found occasional sequence changes in one of five BL cell lines examined, the CDR3 sequence remained essentially unchanged. In contrast to follicular lymphoma, it follows that there is little evidence for clonal evolution in BL.",** Thus, the VH gene nucleotide sequence is relatively fixed and provides a reliable clonal signature for BL.
Using IgM, K and glucose-6-phosphate-dehydrogenase isoenzyme phenotyping, in an era before DNA typing methods were available, Fialkow et al" compared initial and recurrent BLs from 26 patients. In 2 of 31 instances, the phenotypes were discordant for IgM and K-light chain expression, and in I of 8 instances were discordant for glucose-6-phosphate-dehydrogenase phenotype. All cases of concordance occurred with relapse before 5 months of remission duration, and all cases of discordance occurred after 5 months of remission. They hypothesized that discordant cases might be because of the emergence of a second malignant clone.
Barriga et a]*' reported an HIV-positive patient whose BL recurred 27 months after achieving complete remission. Restriction enzyme analysis of the c-myc and Ig heavy-chain loci in the original and recurrent tumor showed two distinct clones. Different breakpoints within c-myc and different mutations in the regulatory or coding regions between initial and recurrent tumors would provide further evidence for their clonal distinctiveness. Alternatively, identical breakpoints would suggest that the two clones are still related and share early genetic events that contribute to the malignant phenotype. Although we did not show translocation of cmyc, the histopathology clearly shows BL. Mutations of p53 have been reported in some BL.24,25 Sequence differences or discordant p53 protein expression would add to the evidence that the initial and recurrent BLs had distinct clonal origins.
The patient reported here had no known predisposing factors for the development of lymphoma yet has developed two clonally distinct BLs. Specifically, there is no history of lymphoproliferative disease, nasopharyngeal carcinoma, chronic myelogenous leukemia, or other cancer in his family,2h nor has there been an increase in severity of infection with Epstein-Barr virus (EBV). His socioeconomic level is on the lower end of that of American society, yet he maintains adequate housing, sanitation, nutrition, and health care. It is unknown if he had been exposed to EBV before the acquisition of his first lymphoma and, as was expected, had positive serology against EBV at his second diagnosis. However, as would be expected for most nonendemic BL, both tumors were negative for EBV as assessed by EBV-encoded RNA-in situ hybridization (EBER-ISH; data not shown).
Observations presented in this report are important, because they confirm that this very late recurrence is caused by the development of another malignant clone rather than a recrudescence of the originally treated lymphoma. Moreover, this is the first report from VDJ sequence evidence, that two BLs developing in the same patient are clonally distinct. In addition, the 15-year interval between the two lymphomas is also the longest period of complete remission followed by relapse thus far described.
Although uncertain, identification of a clonally distinct 
